52.00
-0.70 (-1.33%)
| Penutupan Terdahulu | 52.70 |
| Buka | 52.92 |
| Jumlah Dagangan | 482,153 |
| Purata Dagangan (3B) | 688,319 |
| Modal Pasaran | 1,987,798,784 |
| Harga / Jualan (P/S) | 14.70 |
| Harga / Buku (P/B) | 8.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -103.64% |
| Margin Operasi (TTM) | -52.29% |
| EPS Cair (TTM) | -3.75 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2,471.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.20% |
| Nisbah Semasa (MRQ) | 5.42 |
| Aliran Tunai Operasi (OCF TTM) | -100.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -71.10 M |
| Pulangan Atas Aset (ROA TTM) | -27.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Tarsus Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 8.73% |
| % Dimiliki oleh Institusi | 120.74% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2024 | 1,587,527 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 65.00 (Oppenheimer, 25.00%) | Beli |
| Median | 53.00 (1.92%) | |
| Rendah | 41.00 (Goldman Sachs, -21.15%) | Pegang |
| Purata | 53.00 (1.92%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 45.74 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 15 Nov 2024 | 41.00 (-21.15%) | Pegang | 44.83 |
| Oppenheimer | 14 Nov 2024 | 65.00 (25.00%) | Beli | 46.65 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2024 | Pengumuman | Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors |
| 13 Nov 2024 | Pengumuman | Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements |
| 06 Nov 2024 | Pengumuman | Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 |
| 05 Nov 2024 | Pengumuman | Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer |
| 17 Oct 2024 | Pengumuman | Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% |
| 25 Sep 2024 | Pengumuman | Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |